Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ib, Multi-center, Open Label, Dose Escalation Study of Oral LDE225 in Combination With BKM 120 in Patients With Advanced Solid Tumors

NCT01576666 is registered in ClinicalTrials.gov with Novartis Pharmaceuticals as lead sponsor.

NCT NCT01576666
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01576666 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ib, Multi-center, Open Label, Dose Escalation Study of Oral LDE225 in Combination With BKM 120 in Patients With Advanced Solid Tumors
Lead sponsor
Novartis Pharmaceuticals
Phase
Phase 1
Overall status
Completed
Start date
July 31, 2012
Completion date
April 30, 2015
Enrollment
120 (actual)
Sites
23

Conditions

As the registry lists them; a condition with its own page is linked.

advanced pancreatic adenocarcinoma, advanced solid tumors, dose escalation, gastric cancer, gastroesophageal junction cancer, hormone receptor positive (er+/pr+, and her2-) metastatic breast cancer, metastatic breast cancer, metastatic colorectal cancer, preliminary efficacy, recurrent glioblastoma multiforme, safety, triple negative metastatic breast cancer